WHIPPANY, New Jersey, Aug. 20 [Category: BizPharmaceuticals] -- Bayer USA, an enterprise with core competencies in the life science fields of health care and nutrition, posted the following news:

* * *

Bayer to Present New Phase III Data from Its Cardiovascular, Kidney, and Stroke Clinical Trial Programs at ESC 2026

*

Presentations include investigational late-breaking KERENDIA(r) (finerenone) data in chronic kidney disease (CKD), including a p . . .

Click here for more information about our products